Cargando…
Osteogenic Inhibition in Multiple Myeloma
OBJECTIVE: Multiple myeloma (MM) is a plasma cell malignancy where plasma cells are increased in the bone marrow (BM) and usually do not enter peripheral blood, but produce harmful factors creating problems in these patients (e.g. malignant plasma cells over activate osteoclasts and inhibit osteobla...
Autores principales: | Habibi, Hussain, Abroun, Saeid, Hajifathali, Abbas, Soleimani, Masoud, Kaviani, Saeid, Kalantari, Nasim, Eslahchi, Susan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Royan Institute
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3769610/ https://www.ncbi.nlm.nih.gov/pubmed/24027669 |
Ejemplares similares
-
Effect of The Receptor Activator of Nuclear Factor кB and
RANK Ligand on In Vitro Differentiation of Cord Blood
CD133(+) Hematopoietic Stem Cells to Osteoclasts
por: Kalantari, Nasim, et al.
Publicado: (2016) -
New role of hypoxia in pathophysiology of multiple myeloma through miR-210
por: Saba, Fakhredin, et al.
Publicado: (2018) -
Calprotectin as new potential clinical marker for multiple myeloma
por: Khosravi, Parisa, et al.
Publicado: (2023) -
AntagomiR-19a Induced Better Responsiveness to Bortezomib
in Myeloma Cell Lines
por: Kazemi, Azam, et al.
Publicado: (2021) -
The High Yield Expansion and Megakaryocytic Differentiation
of Human Umbilical Cord Blood CD133(+) Cells
por: Nikougoftar Zarif, Mahin, et al.
Publicado: (2011)